Repligen price target lowered to $220 from $251 at Craig-Hallum

Craig-Hallum analyst Matt Hewitt lowered the firm’s price target on Repligen to $220 from $251 and keeps a Buy rating on the shares following quarterly results. The firm cites near-term headwinds to growth and margins, but notes the base business remains healthy.